Laura Kooienga

2.8k total citations · 3 hit papers
27 papers, 1.2k citations indexed

About

Laura Kooienga is a scholar working on Nephrology, Hematology and Immunology. According to data from OpenAlex, Laura Kooienga has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Nephrology, 9 papers in Hematology and 6 papers in Immunology. Recurrent topics in Laura Kooienga's work include Renal Diseases and Glomerulopathies (14 papers), Platelet Disorders and Treatments (6 papers) and Parathyroid Disorders and Treatments (6 papers). Laura Kooienga is often cited by papers focused on Renal Diseases and Glomerulopathies (14 papers), Platelet Disorders and Treatments (6 papers) and Parathyroid Disorders and Treatments (6 papers). Laura Kooienga collaborates with scholars based in United States, United Kingdom and Australia. Laura Kooienga's co-authors include Geoffrey A. Block, David M. Spiegel, Antonio Bellasi, Paolo Raggi, Gerard Smits, Glenn M. Chertow, Bryan Kestenbaum, Markus Ketteler, Martha S. Persky and John R. Asplin and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Kidney International.

In The Last Decade

Laura Kooienga

23 papers receiving 1.2k citations

Hit Papers

Mortality effect of coronary calcification and phosphate ... 2007 2026 2013 2019 2007 2012 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients
    2007 561 citations Geoffrey A. Block, Paolo Raggi et al. Kidney International profile →
  2. Effects of Phosphate Binders in Moderate CKD
    2012 377 citations Geoffrey A. Block, David C. Wheeler et al. Journal of the American Society of Nephrology profile →
  3. A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
    2023 100 citations Mohit Mathur, Jonathan Barratt et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Kooienga United States 9 1.1k 461 295 202 152 27 1.2k
Fumihiko Koiwa Japan 19 917 0.8× 341 0.7× 251 0.9× 185 0.9× 243 1.6× 93 1.2k
Kátia R. Neves Brazil 12 991 0.9× 329 0.7× 263 0.9× 162 0.8× 123 0.8× 15 1.1k
Vincent Brandenburg Germany 20 730 0.7× 427 0.9× 220 0.7× 232 1.1× 183 1.2× 41 1.4k
Christie Lorriaux France 14 873 0.8× 235 0.5× 306 1.0× 144 0.7× 218 1.4× 34 1000
Brice Mayor France 14 820 0.7× 230 0.5× 306 1.0× 138 0.7× 192 1.3× 30 953
João Frazão Portugal 18 898 0.8× 250 0.5× 377 1.3× 167 0.8× 127 0.8× 66 1.1k
Andrew T. Blair United States 10 656 0.6× 290 0.6× 140 0.5× 195 1.0× 145 1.0× 12 811
Botond Csiky Hungary 11 645 0.6× 187 0.4× 157 0.5× 146 0.7× 121 0.8× 38 982
Ana Carina Ferreira Portugal 13 419 0.4× 195 0.4× 225 0.8× 88 0.4× 142 0.9× 61 875
Naseem Amin United States 6 780 0.7× 232 0.5× 131 0.4× 265 1.3× 189 1.2× 10 1.0k

Countries citing papers authored by Laura Kooienga

Since Specialization
Citations

This map shows the geographic impact of Laura Kooienga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Kooienga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Kooienga more than expected).

Fields of papers citing papers by Laura Kooienga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Kooienga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Kooienga. The network helps show where Laura Kooienga may publish in the future.

Co-authorship network of co-authors of Laura Kooienga

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Kooienga. A scholar is included among the top collaborators of Laura Kooienga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Kooienga. Laura Kooienga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Barratt, Jonathan, Biruh Workeneh, Sung Gyun Kim, et al.. (2025). WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN). Kidney International Reports. 10(2). S769–S770. 2 indexed citations
3.
Kooienga, Laura, Eun Young Lee, Sung Gyun Kim, et al.. (2025). Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy. Kidney International. 108(3). 445–454. 1 indexed citations
4.
Barratt, Jonathan, Mohit Mathur, Adrian Liew, et al.. (2024). The Anti-APRIL Antibody Sibeprenlimab Reduces Circulating Immune Complexes in Patients with IgAN: The Phase 2 ENVISION Randomized Controlled Trial. Journal of the American Society of Nephrology. 35(10S).
5.
Ayoub, Isabelle, Sydney Tang, Laura Kooienga, et al.. (2024). Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors in Adults with IgA Nephropathy in the Ongoing Phase 2 SPARTACUS Trial. Journal of the American Society of Nephrology. 35(10S). 2 indexed citations
6.
Kooienga, Laura, Steven K. Burke, Zhihui Yang, et al.. (2024). Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia. SHILAP Revista de lepidopterología. 5(11). 1652–1661. 2 indexed citations
7.
Sarnak, Mark J., Rajiv Agarwal, Neil Boudville, et al.. (2023). Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrology Dialysis Transplantation. 38(10). 2358–2367. 6 indexed citations
8.
Barratt, Jonathan, Laura Kooienga, Irfan Agha, et al.. (2023). #4337 UPDATED INTERIM RESULTS OF A PHASE 1/2 STUDY OF BION-1301 IN PATIENTS WITH IGA NEPHROPATHY. Nephrology Dialysis Transplantation. 38(Supplement_1). 3 indexed citations
9.
Mathur, Mohit, Jonathan Barratt, Bobby Chacko, et al.. (2023). A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. New England Journal of Medicine. 390(1). 20–31. 100 indexed citations breakdown →
10.
Kooienga, Laura, Robert Małecki, Priscila Preciado, Ping He, & Alex Mercer. (2023). Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE). Journal of the American Society of Nephrology. 34(11S). 979–979. 2 indexed citations
11.
Mathur, Mohit, Tak Mao Chan, Kook‐Hwan Oh, et al.. (2023). A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. Journal of Clinical Medicine. 12(21). 6927–6927. 8 indexed citations
12.
Barratt, Jonathan, Laura Kooienga, Irfan Agha, et al.. (2022). Updated Interim Results of a Phase 1/2 Study of BION-1301 in Patients With IgA Nephropathy. Journal of the American Society of Nephrology. 33(11S). 503–503. 2 indexed citations
13.
Barratt, Jonathan, Laura Kooienga, Irfan Agha, et al.. (2022). MO212: Updated Interim Results of A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients With IGA Nephropathy. Nephrology Dialysis Transplantation. 37(Supplement_3). 5 indexed citations
14.
Chertow, Glenn M., Neil Boudville, Carlos González, et al.. (2021). Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis. Journal of the American Society of Nephrology. 32(10S). 184–184. 1 indexed citations
15.
Block, Geoffrey A., Gerard Smits, Laura Kooienga, et al.. (2018). LB05RANDOMIZED TRIAL OF THE EFFECTS OF FERRIC CITRATE IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation. 33(suppl_1). i637–i638. 2 indexed citations
16.
Block, Geoffrey A., David C. Wheeler, Martha S. Persky, et al.. (2012). Effects of Phosphate Binders in Moderate CKD. Journal of the American Society of Nephrology. 23(8). 1407–1415. 377 indexed citations breakdown →
17.
Bellasi, Antonio, Laura Kooienga, Geoffrey A. Block, et al.. (2009). How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?. Journal of Nephrology. 22(2). 255–262. 32 indexed citations
18.
Kooienga, Laura, Linda F. Fried, Robert Scragg, et al.. (2009). The Effect of Combined Calcium and Vitamin D3 Supplementation on Serum Intact Parathyroid Hormone in Moderate CKD. American Journal of Kidney Diseases. 53(3). 408–416. 38 indexed citations
19.
Block, Geoffrey A., Paolo Raggi, Antonio Bellasi, Laura Kooienga, & David M. Spiegel. (2007). Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney International. 71(5). 438–441. 561 indexed citations breakdown →
20.
Kooienga, Laura. (2007). PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphorus Balance with Daily Dialysis. Seminars in Dialysis. 20(4). 342–345. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fumihiko Koiwa Breakdown of academic impact, for papers by Kátia R. Neves Breakdown of academic impact, for papers by Vincent Brandenburg Breakdown of academic impact, for papers by Christie Lorriaux Breakdown of academic impact, for papers by Brice Mayor Breakdown of academic impact, for papers by João Frazão Breakdown of academic impact, for papers by Andrew T. Blair Breakdown of academic impact, for papers by Botond Csiky Breakdown of academic impact, for papers by Ana Carina Ferreira Breakdown of academic impact, for papers by Naseem Amin
Rankless by CCL
2026